The study analyzed data from two clinical trials (VICTORIA and VICTOR) with a total of approximately 8,000 patients with heart failure and reduced ejection fraction who received vericiguat or placebo.[1][4] Vericiguat is a soluble guanylate cyclade stimulator that has been tested in different groups of patients – in the VICTORIA study in patients with recent worsening heart failure and in the VICTOR study in stable patients without recent worsening.[1][3] A pooled analysis of both studies showed that vericiguat reduced the risk of hospitalization for heart failure and cardiovascular death compared with placebo.[4] The benefits of the drug were most pronounced in patients with a lower level of the NT-proBNP marker (≤6,000 pg/ml), who comprised 88.7% of the participants.[1] The drug is administered once daily and has a favorable safety profile.[1] The results suggest that vericiguat could be a suitable option for selected patients with heart failure and reduced ejection fraction who are already being treated with current standard therapy.[4]